Results 31 to 40 of about 6,134 (265)
Determining Parental Factors for Clinical Trial Attrition in Pediatric Acute Lymphoblastic Leukemia
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background/Objectives Despite high enrollment rates on Children's Oncology Group (COG) protocols, attrition after initial consent is challenging, introducing bias and prolonging trial completion. While adult oncology literature has identified predictors of withdrawal, little is known about caregiver decision‐making for child participation in ...
Kimberly L. Stathas +3 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Together, leukemia and lymphoma account for 38.7% of newly diagnosed pediatric cancer cases in the United States each year. Many caregivers utilize online resources to inform medical health decisions. Understanding the readability of these materials is critical to ensuring comprehensible patient education.
Chloe Strege +6 more
wiley +1 more source
Agroecosistemas, 2021 La producción bananera, es uno de los sectores económicos más importante del Ecuador, debido al aporte que brinda en materia de tributos y plazas de empleo para miles de familias a lo largo de las provincias donde se produce la fruta; el objetivo de la ...
Chuquirima Espinoza, Samuel Efraín +2 more
doaj
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Sickle cell disease (SCD) has undergone major changes in the last decades. Its prevalence has been steadily increasing and numerous advances have been made in the management of the disease. However, the effect in real‐life setting of these major changes is unknown, particularly in a Canadian environment. Procedure We aimed to assess
Maude Cigna +16 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Person‐centred follow‐up care based on evidence‐based clinical practice guidelines and providing individualised information should help to inform and reassure survivors about their medical and psychosocial situation and provide treatment and support where needed.
Gisela Michel +36 more
wiley +1 more source
Los costes en la evaluación de intervenciones farmacéuticas. Los costes en farmacoeconomía
Farmacéuticos Comunitarios, 2011 La evaluación económica de las tecnologías sanitarias, como cualquier intervención farmacéutica, precisa identificar con el mayor detalle posible todos los recursos utilizados en la implementación de la misma. El primer aspecto que se tendrá en cuenta es
Sanz Granda A
doaj
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Japan's 2024 physician work‐style reform introduced legally binding limits on physicians’ working hours, but its impact on education and workforce sustainability in pediatric hematology–oncology (PHO) remains unclear. Procedure We conducted a repeated cross‐sectional study with structured quantitative items and free‐text responses ...
Kiyohiko Kaizu +7 more
wiley +1 more source
Revista Arbitrada Interdisciplinaria Koinonía, 2020 The objective of this research is to propose an optimal accounting management system for property, plant and equipment for the tourist land transport sector of Azuay. Non-experimental descriptive type.
Daysi Yessenia Ortiz-Jara +2 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Ewing sarcoma (ES) and rhabdomyosarcoma (RMS) are aggressive malignancies in children and adolescents where metastases impact prognosis. 18F‐fluoro‐2‐deoxy‐d‐glucose positron emission tomography/computed tomography (FDG‐PET/CT) and bone marrow aspirate and trephine biopsies (BMAT) are used to identify disease involvement.
Imogen Andrews +3 more
wiley +1 more source